Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine

Trial Profile

Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Initial results assessing the (n=27) safety and efficacy of varlitinib in combination with cisplatin and 5-fluorouracil or cisplatin and capecitabine in patients with metastatic solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 26 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top